RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
VIVA Biotech Holdings Stock

VIVA Biotech Holdings Stocks 2024

VIVA Biotech Holdings Stocks

1.94 B

Ticker

1873.HK

ISIN

KYG9390W1015

WKN

A2PH5Q

In 2024, VIVA Biotech Holdings had 1.94 B outstanding stocks, a 0% change from the 1.94 B stocks in the previous year.

The VIVA Biotech Holdings Stocks history

YEARNUMBER OF STOCKS (undefined CNY)
2025e1.94
2024e1.94
20231.94
20221.92
20211.97
20201.57
20191.48
20181.19
20171.16
20161.15

VIVA Biotech Holdings shares outstanding

The number of shares was VIVA Biotech Holdings in 2023 — This indicates how many shares 1.94 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue VIVA Biotech Holdings earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates VIVA Biotech Holdings's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of VIVA Biotech Holdings’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating VIVA Biotech Holdings's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

VIVA Biotech Holdings Aktienanalyse

What does VIVA Biotech Holdings do?

VIVA Biotech Holdings is a Chinese company specializing in the development of pharmaceuticals. It was listed on the Hong Kong Stock Exchange in 2018 and is headquartered in Shanghai. The company started as a small start-up in 2013 but has quickly become one of the industry leaders in pharmaceutical discovery and development. VIVA Biotech Holdings' business model revolves around creating a shared ecosystem for biotechnology start-ups and their customers. The company offers a wide range of services, including target molecule identification and validation, drug candidate optimization, and speeding up the timeline for clinical trials and commercialization. One key aspect of VIVA Biotech Holdings' business model is its VIVA Accelerator programs, which support and foster promising early-stage biotechnology start-ups. These programs provide start-ups with access to state-of-the-art facilities, expert advice, and funding opportunities. The company also operates several divisions focused on the discovery and development of new pharmaceuticals. These divisions include drug candidate synthesis, screening platforms for identifying drug candidates, and structural elucidation of proteins and other molecules. A major focus of VIVA Biotech Holdings is the development of cancer treatments. The company has developed a wide range of drug candidates that specifically target and destroy cancer cells. This includes both small molecules and biological drugs. In addition to cancer research, VIVA Biotech Holdings is also involved in the discovery and development of drugs for other diseases such as inflammatory and metabolic disorders. The company works closely with its customers and partners to develop targeted treatment options. Overall, VIVA Biotech Holdings has achieved an impressive track record in drug discovery and development in recent years. The company has developed a wide range of drug candidates at various stages of clinical development that have the potential to revolutionize the treatment of cancer and other diseases. As a company, VIVA Biotech Holdings is also committed to promoting the biotechnology sector and supporting start-ups and young companies. It is an important player in the Chinese biotech industry and an emerging company in the global pharmaceutical development market. VIVA Biotech Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating VIVA Biotech Holdings's Shares Outstanding

VIVA Biotech Holdings's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in VIVA Biotech Holdings’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding VIVA Biotech Holdings’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in VIVA Biotech Holdings’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about VIVA Biotech Holdings stock

How many stocks are there of VIVA Biotech Holdings?

The current number of stocks of VIVA Biotech Holdings is 1.94 B undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of VIVA Biotech Holdings are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of VIVA Biotech Holdings evolved in recent years?

The number of shares of VIVA Biotech Holdings has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. VIVA Biotech Holdings as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of VIVA Biotech Holdings?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does VIVA Biotech Holdings pay?

Over the past 12 months, VIVA Biotech Holdings paid a dividend of 0.01 CNY . This corresponds to a dividend yield of about 1.86 %. For the coming 12 months, VIVA Biotech Holdings is expected to pay a dividend of 0 CNY.

What is the dividend yield of VIVA Biotech Holdings?

The current dividend yield of VIVA Biotech Holdings is 1.86 %.

When does VIVA Biotech Holdings pay dividends?

VIVA Biotech Holdings pays a quarterly dividend. This is distributed in the months of October, July, October, July.

How secure is the dividend of VIVA Biotech Holdings?

VIVA Biotech Holdings paid dividends every year for the past 2 years.

What is the dividend of VIVA Biotech Holdings?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is VIVA Biotech Holdings located?

VIVA Biotech Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von VIVA Biotech Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of VIVA Biotech Holdings from 7/9/2021 amounting to 0.01 CNY, you needed to have the stock in your portfolio before the ex-date on 6/16/2021.

When did VIVA Biotech Holdings pay the last dividend?

The last dividend was paid out on 7/9/2021.

What was the dividend of VIVA Biotech Holdings in the year 2023?

In the year 2023, VIVA Biotech Holdings distributed 0 CNY as dividends.

In which currency does VIVA Biotech Holdings pay out the dividend?

The dividends of VIVA Biotech Holdings are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von VIVA Biotech Holdings

Our stock analysis for VIVA Biotech Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of VIVA Biotech Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.